Replimune went from an FDA rejection to a resubmission, a positive advisory committee vote, and finally an accelerated regulatory approval for advanced melanoma — all in less than four months. The FDA nod for Replimune’s oncolytic viral therapy, Tudriqev, positions it as a more convenient alternative to an Iovance Biotherapeutics cell therapy that had been the only treatment in this setting.
The post Recovery for Replimune: Accelerated Approval for Cancer Drug Twice Spurned by FDA appeared first on MedCity News.
